ArticleLeukemia2026

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

Thierry Facon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.